返回 Agenda
Exploration of Metabolic Diseases: Is the Liver the New Heart?
Session Chair(s)
Clayton Dehn, MS
Vice President, Clinical Pharmacology Services
High Point Clinical Trials , United States
With the increasing prevalence of metabolic disease, this session will explore the rising incidence of metabolic disease such as diabetes as well as emerging areas of metabolic diseases such as NAFLD/NASH. With new imaging technique enhancements, we observe previously undetected liver scarring progressing to fibrosis and onto cirrhosis. With no NAFLD/NASH-specific treatment to date, the FDA has provided recommendations in this indication.
Learning Objective : Discuss why liver fibrosis is becoming a concern in the pharmaceutical industry and is an area needed for therapy.
Speaker(s)
Liver Let Die: Challenges and Opportunities in Developing Early Interventions for Fatty Liver Disease
Clayton Dehn, MS
High Point Clinical Trials , United States
Vice President, Clinical Pharmacology Services
Understanding the Natural History and Health Burden of Nonalcoholic Fatty Liver Disease (NAFLD): America’s Newest Epidemic
Naim Alkhouri, MD
Texas Liver Institute, United States
Director of the Metabolic Center
Challenges and Opportunities in Clinical Development in Non-Alcoholic Steatohepatitis (NASH): Drugs for NASH Paving the Way
Claudia M. Filozof, DrMed, MD
Covance Inc., United Kingdom
Executive medical director
The DASH to Treat NASH
Melissa Palmer, MD
Shire, United States
Global Development Lead, NASH